Cassava Sciences, Inc. Gains 26.74%

Tue, Dec 24, 2019 at 05:30 PM

Cassava Sciences, Inc. (SAVA:NASDAQ) soared at $4.55, a gain of 26.7%. On Mon 23 Dec 19, SAVA:NASDAQ hit a New 2-Week High of $3.59. The stock appeared on our News Catalysts scanner on Fri 06 Dec 19 at 04:48 PM in the 'BIOTECH' category. From Tue 03 Dec 19, the stock recorded 50.00% Up Days and 40.00% Green Days

About Cassava Sciences, Inc. (SAVA:NASDAQ)

Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.

Top 10 Gainers:

Microbot Medical Inc. (MBOT:NASDAQ), 61.03%
Proteostasis Therapeutics, Inc. (PTI:NASDAQ), 51.01%
CLPS Incorporation (CLPS:NASDAQ), 46.12%
Lineage Cell Therapeutics, Inc. (LCTX:NYSEMKT), 34.52%
TMSR Holding Company Limited (TMSR:NASDAQ), 33.33%
Sienna Biopharmaceuticals, Inc. (SNNA:NASDAQ), 30.7%
Soleno Therapeutics, Inc. (SLNO:NASDAQ), 28.57%
Cassava Sciences, Inc. (SAVA:NASDAQ), 26.74%
Hi-Crush Inc. (HCR:NYSE), 26.25%
Applied Genetic Technologies Corporation (AGTC:NASDAQ), 23.98%